Soliris (eculizumab) data to be presented at American Society of Hematology

December 08, 2006

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that abstracts relating to Soliris™ (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria (PNH) have been published by the American Society of Hematology (ASH). Each of these abstracts will be presented at the 2006 ASH Annual Meeting in Orlando, Florida, December 9th to 12th by leading investigators in the Soliris™ (eculizumab) PNH clinical studies. Copies of the abstracts are available and can be viewed on-line through the ASH website: www.hematology.org/meetings/abstracts.cfm. Access to the on-line abstracts may require registration, for which there is no charge.

The following abstracts will be presented in oral sessions: The following abstracts will be presented in poster sessions:
-end-
About PNH and Soliris(TM)
PNH, a rare and life-threatening form of hemolytic anemia, is an acquired genetic blood disorder characterized by destruction of red blood cells by the body's complement system (a component of the immune system). Patients with PNH lack naturally-occurring complement inhibitors which normally prevent red blood cell destruction. Soliris™ (eculizumab), a long-acting C5 terminal complement inhibitor, is an investigational humanized monoclonal antibody drug that is designed to selectively block terminal complement activation and thereby restore complement inhibition in the blood of patients with PNH. Soliris™ (eculizumab) has been granted Orphan Drug Status in the PNH indication from both the FDA and European regulatory agencies. There currently is no approved therapy specifically available for treatment of PNH.

About Alexion
Alexion Pharmaceuticals is a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life- threatening medical conditions. Alexion is engaged in the discovery and development of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. Alexion's lead product candidate, Soliris™ (eculizumab), is currently undergoing evaluation in several clinical development programs, including for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Under the Special Protocol Assessment (SPA) process, the FDA has agreed to the design of protocols for the two phase III trials of Soliris™ (eculizumab) in PNH patients. In January, 2006, Alexion announced that the first of those two PNH trials, the TRIUMPH study, achieved its co- primary endpoints with statistical significance. In June 2006, Alexion announced that interim results from the second of those two PNH trials, the SHEPHERD study, showed that eculizumab appeared to be safe and well tolerated and that all primary and secondary efficacy endpoints were achieved with statistical significance. In September, 2006, Alexion applied for marketing authorization with both the United States Food and Drug Administration and the European Medicines Evaluation Agency for the use of Soliris™ (eculizumab) in PNH patients. Results from the TRIUMPH and SHEPHERD trials served as the primary basis for the marketing applications filed in the United States and Europe. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.

This news release contains forward-looking statements, including statements related to potential benefits and commercial potential for Soliris™ (eculizumab), clinical trial results, the progress of Soliris™ (eculizumab) towards commercial sales, timing for acceptance of, and potential regulatory decisions with respect to, marketing applications for Soliris™ (eculizumab). Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including delays in completing ongoing clinical trials, delays in completing analysis of clinical trial results, requests by the FDA or other regulatory authorities for additional information or data either prior to their acceptance of our submissions for filing or after their review of our submissions, timing and evaluation by regulatory agencies of the results of these and other clinical trials, the results of pre-clinical or clinical studies (including termination or delay in clinical programs), the need for additional research and testing, decision of the FDA or other regulatory authorities not to approve (or to materially limit) marketing of Soliris™ (eculizumab), delays in arranging satisfactory manufacturing capability, delays in developing commercial infrastructure, inability to acquire funding on timely and satisfactory terms, delays in developing or adverse changes in commercial relationships, the possibility that results of earlier clinical trials are not predictive of safety and efficacy of Soliris™ (eculizumab), the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms, the risk that third party payors will not reimburse for the use of Soliris™ (eculizumab) at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2006 and in our other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward- looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

Euro RSCG Life NRP

Related Hematology Articles from Brightsurf:

Study finds gender disparities in hematology research success
Hematologists who complete a mentored training program experience greater levels of academic success than those who do not; however, a study published today in Blood Advances suggests a slight discrepancy in success levels between male and female hematologists.

Survey suggests mentorship in medical school is vital to future of hematology
A survey of US hematology-oncology fellows suggests medical school plays an important role in shaping their interest in pursuing careers in hematology, particularly when students are exposed to hematology and oncology as part of core clerkships in internal medicine and pediatrics.

JAK inhibitors associated with aggressive lymphoma
Austrian researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas.

For young adults with blood cancer, pediatric centers may improve survival
Adolescents and young adults with acute leukemia have a survival advantage if they receive treatment at a pediatric cancer center versus an adult center, according to a new study.

Global hematology diagnostics market estimated to expand at a robust CAGR over 2021
Hematology includes various IVD technologies such as blood analysis, flow cytometry, immunodiagnostics, molecular diagnostics, hemostasis, histology, and cytology.

Late-breaking hematology abstracts signal new, near-term therapeutic options for patients
In four clinical trials being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report promising results suggesting patients with blood disorders and several types of cancer will soon have significantly expanded options for treatment.

American Society of Hematology announces top trainee abstracts of 2016 ASH Annual Meeting
The American Society of Hematology (ASH) is pleased to recognize the following trainees with the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow at the 58th ASH Annual Meeting Dec.

ASH to expand family of blood journals with launch of new cutting-edge publication
The American Society of Hematology (ASH) will launch an open-access journal to complement Blood, its flagship publication and the most-cited journal in hematology.

Study finds common genetic variants that double risk for blood clots in African Americans
New research published online today in Blood the Journal of the American Society of Hematology, identifies common genetic variants predominantly found in African Americans that double their risk for blood clots.

Mount Sinai researchers present results at American Society of Hematology Meeting
Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2015 American Society of Hematology meeting Dec.

Read More: Hematology News and Hematology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.